Moreover, low-risk patients displayed a higher proportion of CXCL13 + CD4+ and CXCL13 + CD8 + T cells, indicating a more active tumor immune microenvironment and enhanced responsiveness to immunotherapy66. The gene discussed is CXCL13; the disease is neoplasm.